Who is sponsoring NCT05572983?

NCT05572983 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05572983?

Interventions in NCT05572983: Chidamide combined with CHOP, Chidamide.

Is NCT05572983 still recruiting?

NCT05572983 is currently recruiting now. Last updated 10 October 2022.

Last reviewed 2022-10-10 · How we verify

NCT05572983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Recruiting now Phase 2 Last updated 10 October 2022

What this trial tests

Phase 2 trial testing Chidamide combined with CHOP in Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype in 47 participants. Currently enrolling.

Timeline

1 September 2022

Primary endpoint
1 September 2024

1 September 2026

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	1 September 2022
Primary completion	1 September 2024
Estimated completion	1 September 2026
Sites	1 location across China

Drugs / interventions tested

Chidamide combined with CHOP — full drug profile →
Chidamide — full drug profile →

Conditions studied

Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype — all drugs for Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05572983 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 10 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05572983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing